Greenland Mines Sets $5.00 Price for $20M Best-Efforts Offering
GRML is trading near its 52-week low of $4.37 (7.7% above the low) on elevated volume (2.9× avg).
Summary
A $20 million best-efforts offering was priced at $5.00 per share, with net proceeds of about $18.6 million targeted for the Sarfartoq rare earth acquisition.
Key Events · Financing and Capital Events · GRML
-
$20M Offering Priced at $5.00/Share
The offering consists of 1,632,783 common shares at $5.00 and 2,367,217 pre-funded warrants at $4.9999, for total gross proceeds of $20 million.
-
Net Proceeds of $18.6M for Sarfartoq
After a 7% placement agent fee ($1.4M) and estimated expenses, net proceeds are approximately $18.6 million, earmarked for the Sarfartoq rare earth project acquisition.
-
Dilution to New Investors
New investors face immediate dilution of $1.14 per share, with pro forma net tangible book value at $3.86 per share versus the $5.00 offering price.
-
Reverse Split Context
The offering follows a 1-for-50 reverse split effective August 24, 2026, implemented to regain Nasdaq's $1.00 minimum bid price requirement by the September 14, 2026 deadline.
Analysis · GRML · Life Sciences
The terms of a $20 million best-efforts offering have been finalized, with 1.63 million common shares priced at $5.00 and 2.37 million pre-funded warrants at $4.9999. A 7% placement agent fee leaves roughly $18.6 million in net proceeds earmarked for the Sarfartoq rare earth project acquisition. For a company with a market cap near $15 million, this is a substantial capital raise, and it comes just days after a 1-for-50 reverse split implemented to regain Nasdaq compliance. The offering is dilutive to existing holders, but the proceeds are critical to closing the Sarfartoq deal and extending the company's runway amid going-concern doubts.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 36.4% of the 1919 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GRML was trading at $4.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15M. The 52-week trading range was $4.37 to $38.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.